Mandate

Vinge has assisted Novozymes Biopharma DK A/S

November 08, 2011

Vinge has assisted Novozymes Biopharma DK A/S in the sale of Novozymes Biopharma Sweden AB to Repligen Corporation. Novozymes is the world leader in bio innovation with industrial enzymes, microorganisms, and biopharmaceutical ingredients as its business. Novozymes generated sales of DKK 9,724 million and EBIT of DKK 2,117 million in 2010.

Repligen Corporation is a leading supplier of critical technologies and ingredients used to manufacture biologic drugs. Repligen's corporate headquarters are in Massachusetts, USA.

Vinge’s team has primarily consisted of Björn Mullaart (partner), Karin Ebbinghaus (senior associate and Karin Engström (associate).

Related

Vinge advises Humana in its acquisition of Team Olivia Norge AS

Humana Group ("Humana") strengthens its offering of high-quality care services in Norway as Human Care Holding AS ("Humana Norway") has entered into an agreement to acquire Team Olivia Norge AS for a purchase price of million SEK 341 on a cash- and debt-free basis.
May 17, 2024

Vinge advises Stendörren in connection with issuance of green capital securities and tender offer

Vinge has advised Stendörren Fastigheter AB in connection with its issuance of green subordinated and perpetual capital securities in an amount of SEK 300 million (within a framework of SEK 400 million) and its parallel tender offer in respect of its previously issued capital securities.
May 17, 2024

Vinge has advised Stockholm Exergi AB in connection with the conclusion of a permanent carbon removal agreement with Microsoft, the world’s largest to date

Vinge has advised Stockholm Exergi in connection with the conclusion of a permanent carbon removal agreement with Microsoft, covering 3.33 million tonnes of permanent carbon removals from bio-energy with carbon capture and storage (BECCS) at Värtan, Stockholm. The agreement is the world’s largest permanent carbon removal deal to date.
May 16, 2024